ArticleCHEST pulmonary2024
Impact of High-Frequency Chest Wall Oscillation on Health Care Resource Use and Economic Outcomes in Adult Patients With Non-Cystic Fibrosis Bronchiectasis in the United States: A Pre-Post Cohort Analysis.
Article in CHEST pulmonary, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Characteristics of Medicare and Medicaid Patients Initiating Volara Respiratory Therapy: A Medical Claims Study.Advances in therapy · 2026Article
- High frequency chest wall oscillation for airway clearance in bronchiectasis.Frontiers in rehabilitation sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Airway clearance therapy is prescribed to patients with bronchiectasis, but limited evidence exists demonstrating the effectiveness of medical device treatment options. Research Question: What is the impact of high-frequency chest wall oscillation therapy (HFCWO) on health care resource use (HCRU) and economic outcomes in patients with bronchiectasis in the United States? Study Design and Methods: A retrospective pre-post cohort study was conducted using the PharMetrics Health Plan Claims Database. The study included commercially insured adult patients with bronchiectasis receiving HFCWO between January 2009 and February 2018. Health care claims were compared 12 months before and after initiation of HFCWO. End points included all-cause and disease-specific HCRU and costs. Comparisons were conducted using McNemar's test for categorical variables and the Wilcoxon signed-rank test for continuous variables. Results: A total of 255 patients were included. Mean age was 55.6 years, and 58% were high risk. Compared with baseline, significant reductions in all-cause hospital length of stay (9 vs 6 days; Interpretation: HFCWO therapy is associated with lower HCRU 12 months after initiation of therapy. Further health economic studies are required to determine if cost savings offset cost of the device after 1 year.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.